截至2025年7月11日 09:34，恒生医疗保健指数(HSHCI)强势上涨1.64%，成分股药明康德(02359)上涨 9.84%，同源康医药-B(02410)上涨7.22%，药明合联(02268)上涨6.73%，博安生物(06955)，药明生物 (02269)等个股跟涨。恒生医疗ETF(513060)上涨1.04%，最新价报0.58元。拉长时间看，截至2025年7月 10日，恒生医疗ETF近2周累计上涨3.21%。 流动性方面，恒生医疗ETF盘中换手2.29%，成交1.85亿元。拉长时间看，截至7月10日，恒生医疗ETF 近1月日均成交20.92亿元，排名可比基金第一。 消息面上，7月10日晚间，药明康德发布业绩预告，预计上半年经调整归母净利润约人民币63.15亿元， 同比增长约44.43%；预计上半年实现归属于本公司股东的净利润约人民币85.61亿元，同比增长约 101.92%，其中包含了出售联营公司部分股权所获得的投资收益；本期基本每股收益预计约人民币3.01 元/股，同比增长约106.16%。业绩增长得益于其 "一体化、端到端" 业务模式，以及新能力拓展和产能 建设等。 广发证券认为，我国创新药发展 ...

Core Insights - The A-share market concluded the first half of 2025 with a structural market trend, showing significant performance divergence among public funds, with an average return of 4.13% and over 87% of funds achieving positive returns [2][3] - The top-performing funds were primarily focused on the pharmaceutical and biotechnology sectors, while some funds heavily invested in new energy and artificial intelligence themes faced performance challenges [2][3] Fund Performance Overview - The top fund, Huatai Hong Kong Advantage Selection A, achieved a remarkable return of 86.48%, while the bottom fund, Qianhai Kaiyuan Artificial Intelligence A, recorded a loss of -20.57%, resulting in a performance gap of 107 percentage points [2][3][5] - The top 30 funds exhibited three notable characteristics: a strong rise of North Exchange theme funds, widespread success of pharmaceutical theme funds, and robust performance of Hong Kong Stock Connect innovative drug ETFs [3][5] Top 30 Funds Summary - The top three funds were: 1. Huatai Hong Kong Advantage Selection A (86.48%) 2. CITIC Construction Investment North Exchange Selection Two-Year Open A (82.45%) 3. Great Wall Pharmaceutical Industry Selection A (75.18%) [4][5] - The North Exchange 50 Index rose approximately 39.45% in the first half of the year, with related theme funds dominating the top ten performance rankings [3][5] Bottom 30 Funds Summary - The bottom fund, Qianhai Kaiyuan Artificial Intelligence A, had a return of -20.57%, with most underperforming funds being mixed and stock funds, showing losses between -12.43% and -20.57% [6][7] - The underperforming funds were heavily concentrated in technology and AI sectors, which faced significant downturns, contrasting with the strong performance of healthcare and innovative drug sectors in top-performing funds [8][9] Market Outlook - The A-share market is expected to present a "volatile upward" trend in the second half of 2025, supported by a series of domestic growth policies and monetary easing [11][12] - Investment strategies should balance high-growth sectors with stable dividend assets, focusing on innovative drugs and technology while considering potential external uncertainties [12]

A股创新药概念早盘涨幅居前，常山药业涨超16%，康辰药业涨停，联环药业涨超9%，广生堂、立方制 药、华北制药等个股跟涨。日前国家医保局公布工作方案，今年将首次制定商保创新药目录。 ...

Core Viewpoint - The innovative drug concept continues to show strong performance, with significant stock price increases for companies such as Boteng Co. and Changshan Pharmaceutical, which rose over 15% [1] Group 1: Stock Performance - Boteng Co. and Changshan Pharmaceutical saw stock increases of over 15% [1] - WuXi AppTec experienced a nearly 9% rise [1] - Other companies like Kylin Pharmaceutical, Guangsheng Pharmaceutical, and Yifang Bio also saw stock increases of over 5% [1] Group 2: Policy Announcement - On July 10, the National Healthcare Security Administration announced the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, as well as the Commercial Health Insurance Innovative Drug Catalog [1] - The plan specifies that the adjustments to the basic medical insurance drug catalog and the establishment of the commercial health insurance innovative drug catalog will occur simultaneously in 2025 [1]

2025 年 07 月 11 日 双融日报 --鑫融讯 分析师：万蓉 S1050511020001 wanrong@cfsc.com.cn 市场情绪：76 分（较热） 最近一年大盘走势 资料来源：Wind，华鑫证券研究 -15 -10 -5 0 5 10 15 20 25 (%) 沪深300 相关研究 ▌ 华鑫市场情绪温度指标：（较热） 华鑫市场情绪温度指标显示，昨日市场情绪综合评分为 76 分，市场情绪处于"较热"。历史市场情绪趋势变化可参 考图表 1。 ▌ 热点主题追踪 今日热点主题：数据、跨境支付、创新药 1、数据主题：据《央视新闻》报道，为了破解数据流通 交易效率不高的难题，国家数据局、国家市场监督管理总局 首次推出数据流通交易便利化举措，发布数据流通交易合同 示范文本，为有需要的经营主体提供参考。有关企业反馈， 合同应用将大幅降低数据流通交易的协商成本，预计可提升 30%的效率。相关 标 的：奥飞数据（ 300738）、易华录 （300212） 2、跨境支付主题：7 月 4 日，央行发布《人民币跨境支 付系统业务规则（征求意见稿）》，向社会公开征求意见至 8 月 3 日。此次修订简化境外机构参与条件 ...

港股开盘，恒生指数开涨0.02%，恒生科技指数开跌0.28%；加密货币概念连日走强，创新药概念回 升；知行科技(01274.HK)获某头部自主品牌5款车型的定点函，涨超14%；欧科云链(01499.HK)涨超 6%；药明康德(02359.HK)报盈喜涨4.8%。 ...

恒瑞医药 20250709 摘要 恒瑞医药受益于国内外医药市场回暖及海外投资者关注，预计 2025- 2027 年营收将分别达到 330 亿、378 亿和 446 亿，增速分别为 18%、14.8%和 17.8%；归母净利润预计分别达到 74 亿、86 亿和 103 亿，增速分别为 17%、16.7%和接近 20%。 恒瑞医药临床管线丰富，拥有 132 条管线，其中 31 条已申报上市或处 于后期申报阶段，57 条已披露靶点，另有大量未披露管线，显示出强大 的未来竞争力，预计未来几年创新药获批上市数量将显著增加。 基于收入与利润结构优化及创新药上市数量增加，恒瑞医药市值有望重 回 5,000-6,000 亿元水平，公司近年来完成销售改革并积极推进国内外 创新药业务发展，目前 3,000 亿元市值档口具有良好发展前景。 恒瑞医药通过"借船出海"策略推进国际化，海外竞争力强劲，但 A 股 市场对其海外业务估值尚未充分体现。2023-2025 年 BD 利润分别为 7 亿、27 亿和预计 30-40 亿，将推动公司重回白马股逻辑，预计明年市 盈率为 30-35 倍，利润增速为 20%-30%。 恒瑞医药近期市场表现 ...

Summary of the Conference Call Records Industry Overview: CRO and CDMO Key Points on CRO Industry - The CRO (Contract Research Organization) industry is facing challenges due to intensified competition and weakened profitability after rapid capacity expansion [1][4] - Orders for CRO companies have decreased due to obstacles in innovative drug financing and changes in pharmaceutical policies, leading to a difficult destocking phase [1][4] - In 2024, the number of drug clinical trials in China is expected to grow by 16%, with Phase III trials increasing by 31%, indicating a push in innovative drug development [1][5] - The proportion of BE (Bioequivalence) trials is close to 50%, while Phase I trials have decreased, suggesting a slowdown in early clinical trials [1][5] - Major CRO companies like Zhaoyan New Drug and Tigermed are still expanding their workforce despite the pressure on profitability, indicating market share growth [1][6] Key Points on CDMO Industry - The CDMO (Contract Development and Manufacturing Organization) industry is significantly driven by large orders, particularly from COVID-19 drug commercialization [2][7] - From 2021 to 2023, major companies like WuXi AppTec, Kelun, and Boteng collectively generated $4.2 billion in revenue from large orders, with profits reaching $1.7 billion [2][7] - The development of the peptide industry is crucial for CDMO companies, with products like Semaglutide driving growth for companies like Nuotai and WuXi AppTec [3][8] - The ADC (Antibody-Drug Conjugate) industry is expected to maintain a compound annual growth rate of over 35% until 2030, reflecting strong demand for outsourcing services [3][8] Future Trends and Opportunities - The CRO industry is undergoing a transformation as companies adjust structures and optimize resource allocation to survive [4][6] - The introduction of new listing standards for unprofitable companies may alleviate financing issues for innovative drug firms, potentially boosting CRO demand [4][6] - The potential of alphablenton, a small molecule drug for chronic disease treatment, is highlighted, with a projected sales figure exceeding $29 billion by 2035 [3][11] - The market for chronic disease treatments is expected to grow significantly, with the global adult obesity population projected to rise from 760 million in 2020 to over 1 billion by 2030 [11][12] Additional Insights - The CRO industry is currently experiencing a downturn, with many small companies facing survival challenges, while leading firms are expanding their market share [4][6] - The complex synthesis routes of products like alphablenton contribute significantly to CDMO value, indicating a shift towards more specialized and high-value offerings [10][11] - The pain management market is projected to exceed $120 billion by 2027, with new drug developments addressing unmet clinical needs [13][14] This summary encapsulates the critical insights from the conference call, focusing on the current state and future outlook of the CRO and CDMO industries, along with emerging opportunities and challenges.

Group 1: Policy and Regulatory Updates - The National Healthcare Security Administration released the adjustment plan for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance drug catalog, along with guidelines for commercial health insurance innovative drug catalog adjustments and negotiation rules for drug renewals [1] - The National Medical Products Administration held a national drug business supervision meeting, emphasizing the need for continued risk assessment and the fight against illegal activities in the pharmaceutical sector [2] Group 2: Company Developments - Novo Nordisk's 7.2mg semaglutide application for weight management has been accepted by the European Medicines Agency (EMA), based on positive results from Phase III STEP UP studies [4] - Ascentage Pharma's new drug lisatoclax has received conditional approval from the National Medical Products Administration for use in adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma [5] - Anke Bio announced a collaboration with Shengji Pharmaceutical for the exclusive agency of a recombinant human follicle-stimulating hormone-CTP fusion protein injection in mainland China and Hong Kong, Macau, and Taiwan [7] - Cornerstone Pharmaceuticals plans to place 100 million shares at a price of HKD 4.72 per share, aiming to raise a total of HKD 472 million as part of its financing plan [8] Group 3: Financial Performance - WuXi AppTec expects to achieve approximately CNY 20.799 billion in revenue for the first half of 2025, a year-on-year increase of about 20.64%, with adjusted net profit expected to be around CNY 6.315 billion, reflecting a growth of approximately 44.43% [10] - ST Sihuan anticipates a half-year revenue of CNY 180 million to CNY 190 million, representing a growth of 70.12% to 79.57%, but expects a loss of CNY 9 million to CNY 13 million [12] Group 4: Industry Collaborations - Baiao Biotechnology and BeiGene have reached a global licensing agreement for antibody molecules, which includes upfront payments and milestone payments based on development and commercialization [14]

Group 1 - The report highlights high-growth potential sectors for Q2 2025, including optical modules, diesel generators, innovative pharmaceuticals, and deep-sea technology, driven by increasing demand and supportive policies [2][22][23] - Key themes identified include anti-involution for high-quality industry development, deep-sea technology as a pillar of marine economic strategy, and the acceleration of global stablecoin regulatory frameworks [2][23] - The report notes that the central bank is enhancing financial support for the real economy and expanding the technical standard system for emerging industries [2][23] Group 2 - The report on interest rates indicates that the net issuance of government bonds will remain relatively high in the second half of the year, with a more uniform monthly issuance pattern expected [3][28] - It is anticipated that the central bank will continue to use various tools to stabilize the funding environment, with potential for a reserve requirement ratio cut in the third quarter [3][30] - The bond market is experiencing a shift from a bear to a bull market, with a notable correlation between stock and bond performance observed in the second quarter [5][31] Group 3 - The report on Chip Dynamics (688582) indicates that the company is a leader in MEMS sensors, with projected revenues of 4.05 billion yuan and a net profit of 2.22 billion yuan for 2024, maintaining a gross margin above 70% [9][35] - The company has achieved a 23.45% market share in MEMS gyroscopes, reflecting a 14 percentage point increase since 2019, and is positioned to benefit from the growth in smart driving and industrial automation [9][35][36] - The IMU segment is expected to grow rapidly, with a CAGR of 175.8% from 2021 to 2024, driven by demand in low-altitude economy, smart driving, and humanoid robots [9][36][37] Group 4 - The report on Kangnait Optical (02276) forecasts a net profit increase of no less than 30% for the first half of 2025, driven by global strategic expansion and product structure optimization [11] - The company is enhancing its supply chain resilience by establishing a new high-end lens production line in Japan, which will mitigate tariff risks and ensure stable supply to the U.S. market [11] - The report anticipates continued growth in the resin lens market, with a focus on functional and customized lenses, leading to improved profitability [11] Group 5 - The report on Jinhui Industrial (002597) highlights the approval of D-alloheptulose as a food ingredient, marking a significant step in aligning domestic applications with international standards [12][16] - The company is positioned as the second approved enzyme manufacturer for D-alloheptulose in China, showcasing its technological leadership in functional sweeteners [12][16] - The projected net profits for Jinhui Industrial are 1.171 billion yuan, 2.118 billion yuan, and 2.365 billion yuan for 2025-2027, maintaining a "buy" rating [12][16]